Pip Nicolson/X
Jun 6, 2025, 10:56
Pip Nicolson Highlights Key PITT Case Insight on Anti-PF4 Antibody Testing
Pip Nicolson, Associate Clinical Professor in Cardiovascular Medicine (Haematology) at University of Birmingham, shared on X:
“Thank you Prof. Makris for your clear and concise commentary on our PITT case in the British Journal of Hematology.
Take home message: test anyone with the combination of thrombosis and thrombocytopenia for anti-PF4 antibodies (by ELISA) and have a low threshold for starting non-heparin anticoagulation.”
You Can Find More Posts Featuring Pip Nicolson on Hemostasis Today.
Title: PF4-associated immune thrombocytopenia and thrombosis (PITT)—More than heparin and vaccines
Author: Michael Makris
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS